By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
ACR50 response was similar in olokizumab as compared to adalimumab.
ACR70 responses were not checked.
Similar Side effects were noted in olokizumab as other IL6 receptor blockers such as transaminitis.